Veena Shankaran,1,2 Shasank Chennupati,1 Hayley Sanchez,1 Qin Sun,1 Li Li,1 Catherine Fedorenko,1 Abdalla Aly,3 Marcus Healey,3 Brian Seal3 1Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 2Division of Medical Oncology, University of Washington, Seattle, WA, USA; 3AstraZeneca, Gaithersburg, MD, USACorrespondence: Veena ShankaranClinical Research Division, Fred Hutchinson Cancer Research Center, 825 Eastlake Ave. E, MS G4-830, Seattle, WA, 98109, USATel +1 206 667-7844Fax +1 206 606-2042Email vshank@uw.eduIntroduction: Though the treatment landscape for hepatocellular carcinoma (HCC) has evolved significantly with the refinement of liver-directed therapy techniques and the introduction of new drugs, few studies have investigated the impact of the changing treatment landscape on lifetime treatment costs, particularly in Barcelona Clinic Liver Cancer (BCLC) stage C disease. We sought to investigate real-world clinical characteristics, treatment patterns, and healthcare costs in a cohort of HCC patients treated at a single high-volume institution in Washington (WA) state.Methods: We conducted a retrospective cohort study of patients diagnosed with HCC between 2007 and 2018 using abstracted electronic medical record (EMR) data linked to cancer registry data and health claims from commercial plans, Medicare, and Medicaid. We described clinical and treatment characteristics, including BCLC stage and Child Pugh score. We investigated median survival and mean lifetime treatment costs by BCLC stage using Kaplan–Meier cost estimator methods. A multivariate Cox proportional hazards model was used to investigate factors associated with overall survival.Results: The final cohort included 215 patients, the majority of whom were white (71%), male (68%), and with underlying hepatitis C (61%). Mean per patient lifetime costs were highest in BCLC A and BCLC C patients. Mean lifetime costs in BCLC A patients ($292,134) was driven by surgery, hospital, pharmacy, imaging, and outpatient costs. Chemotherapy costs were highest in BCLC C patients, though not the predominant area of spending. Median survival was highest in patients with BCLC 0 and A disease; BCLC stage C and higher area deprivation index (ADI) were associated with poorer survival.Conclusion: In a cohort of WA state HCC patients, mean lifetime costs were highest in patients with BCLC A disease, attributable to surgery and hospital costs. As increased utilization of newer and less toxic therapies improves survival in BCLC C patients, mean lifetime costs in this group may also rise.Keywords: hepatocellular carcinoma, health economics, health services research, cost of care
